How Changing Dynamics of Anticonvulsants Market are Reflecting on Growth Strategies of Players:Johnson & Johnson (J&J), Novartis AG, UCB Group, GlaxoSmithKline plc, Pfizer Inc., Abbott Laboratories, Cephalon Inc.

Anticonvulsants, also commonly known as antiepileptic drugs or antiseizure drugs are a diverse group of pharmacology agents used in the treatment of epileptic seizures. Epilepsy is a chronic disorder resulting in repeated and unprovoked seizures. Epileptic seizures are commonly referred as convulsions. Anticonvulsants are mainly used for treatment of epileptic seizures. Epileptic seizures are caused by disturbance in the electrical activity of the brain. In addition, anticonvulsants are also used in treatment of bipolar disorder and in neuropathic pain management.

Anticonvulsants Market: Key Players -Some of the key players, contributing to global anticonvulsants drug market, are Johnson & Johnson (J&J), Novartis AG, UCB Group, GlaxoSmithKline plc, Pfizer Inc., Abbott Laboratories, Cephalon Inc. and Shire plc. Pfizer has been estimated to cover the largest market share in the antiepileptic market, accounting for close to one-third of total revenues of the market with it two leading brands.

Download sample copy of this report:
https://www.futuremarketinsights.com/reports/sample/REP-GB-1337

Anyone could potentially have a single epileptic seizure at some point in their lives. This is not the same as having epilepsy, which is a tendency to have seizures that start in the brain. Epilepsy can affect people of any age group. Though brain injury, brain cancer, drug and alcohol misuse and stroke are some of the reasons for epileptic seizures, the exact reason for convulsions is not known. Some of the common symptoms which occur before convulsions include, visual loss, strange feeling, nausea, numbness in body parts, headache and racing thoughts.

Anticonvulsants Market: Drivers and Restraints

Increasing awareness about the anticonvulsants available in the market, patent expiration of many blockbuster drugs are some of the major factors that are driving the global anticonvulsants market towards growth. There are now 24 antiepileptic drugs (AEDs) approved for use in epilepsy in the US by FDA. Moreover, three trends involving consumption of AEDs have become clinically important and must be considered by all who treat patients with epilepsy. These trends include issues of generic substitution of AEDs, pharmacogenomics predicting serious adverse events in certain ethnic populations, and the issue of the suicide risk involving the entire class of AEDs. While, high costs and unavailability of convenient dosage forms of both generic and branded anticonvulsants are restraining the growth of novel therapies in the anticonvulsants market.

Anticonvulsants Market: Segmentation

Anticonvulsants market is segmented based on product type, application, end user and geography.

Based on product type, the anticonvulsants market is segmented as follows:

Barbiturates
Aldehydes
Benzodiazepines
Aromatic allylic alcohols
Carboxamides
Bromides
Carbamates
Sulfonamides
Fructose derivatives
Pyrrolidines
Triazines
Fatty acids
Oxazolidinediones
Ureas
GABA analogs
Propionates
Hydantoins
Pyrimidinediones
Valproylamides (amide derivatives of valproate)
Others
Based on application, the anticonvulsants market is segmented as follows:

Epilepsy
Fibromyalgia
Migraine
Neuropathic pain
Bipolar disorder
Anxiety
Borderline personality disorder
Based on end user, the anticonvulsants market is segmented as follows:

Hospitals
Clinics
Ambulatory surgical clinics

Anticonvulsants Market: Overview

Seizures are expected to result in physical, psychological and social repercussions. People with epilepsy could adhere rigorously to their medication regimes in order to prevent these deleterious outcomes. Treatment of epileptic seizures has led to the growth of anticonvulsants market. Barbiturates were the first antiepileptic drugs. These are more effective and tolerable than bromides. Hydantoins are the first to be known as modern antiepileptic drugs. Succinimides are an old group of drug which are rarely prescribed nowadays. Consequently with these antiepileptic or antiseizure drugs, anticonvulsants market is growing immensely leaving a significant impact on the treatment of epileptic seizures. The antiepileptic drug market is threatened by generic completion, which has been increasing dramatically in the face of patent expirations among several of the major branded antiepileptics. However, there have been cases where generic antiepileptic drugs have not been as efficacious as their branded counterparts have.

Buy Now to Get 10% Off and Free Customization as per Requirement:
https://www.futuremarketinsights.com/checkout/1337

Anticonvulsants Market: Region-wise Outlook

Region wise, the global anticonvulsants marketis classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. Currently, North America dominates the anticonvulsants market followed by Europe. Asia-Pacific is expected to emerge as a lucrative region, owing to factors such as increasing healthcare spending, improving healthcare infrastructure, and increasing demand for drugs. Given these factors, the market for anticonvulsants is likely to grow rapidly in Asia-Pacific region.

Future market insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States

About Us
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

This release was published on openPR.